Mesenchymal stem cell therapy for endometrial injury: a meta-analysis of preclinical studies
Liu Y., Koubanani ZG., Jia D., Ma M.
Meta-analysis, published in BMC Womens Health (2025) — summary generated from the PubMed abstract.
Relatively higher-quality human studies compared with other topics in this database, e.g. multiple RCTs or systematic reviews. This does not mean it is standard or approved care.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Meta-analysis
- Journal
- BMC Womens Health (2025)
- Reported sample size
- —
- Source database
- Europe PMC
- PMID
- 41408243
- PMCID
- PMC12822315
- DOI
- 10.1186/s12905-025-04211-2
Abstract (original English)
BACKGROUND: Endometrial injury is a common cause of menstrual changes, abortion, and even infertility in women, including intrauterine adhesions (Asherman’s syndrome) and a thin endometrium. Hysteroscopic surgery and drug treatment are currently the main treatment methods; however, their effect is not satisfactory. Increasingly, studies have demonstrated that mesenchymal stem cells (MSCs) may be a safe and promising option for treating endometrial injury. This study aimed to evaluate the efficacy of MSCs in an endometrial injury model. METHODS: We searched PubMed, Cochrane Library, Web of Science, and EMBASE from the establishment of the databases to December 2023. Preclinical studies examining the role of MSCs in treating endometrial injury were included. The main outcome measures were the endometrial thickness, fibrosis area ratio, and recovery of reproductive function. Risk of bias assessment was performed using the SYRCLE tool. RevMan 5.3 was used for the meta-analysis and testing heterogeneity. RESULTS: A total of 10 Randomized Controlled Trials (RCTs) involving 230 animals were included. The analysis showed that after treatment with MSCs, the endometrium was significantly thickened (WMD 115.01 μm, 95% CI (94.07–135.95 μm)), the area ratio of endometrial fibrosis reduced (WMD − 29.88, 95% CI (− 36.61–−23.15)), and the pregnancy rate increased (RR 4.60, 95% CI (2.09–10.13))
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
Evidence level
Relatively higher-quality human studies compared with other topics in this database, e.g. multiple RCTs or systematic reviews. This does not mean it is standard or approved care.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.